News Release

MCG receives $100,000 Grand Challenges Explorations grant for innovative global health research

Grant and Award Announcement

Medical College of Georgia at Augusta University

MCG Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research

image: The Medical College of Georgia announced today that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr. Pandelakis A. Koni titled "Antibody-Dependent Cellular Cytotoxicity Targeted Against HIV-1 Env Glycans." view more 

Credit: Medical College of Georgia

AUGUSTA, Ga. – The Medical College of Georgia announced today that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr. Pandelakis A. Koni titled "Antibody-Dependent Cellular Cytotoxicity Targeted Against HIV-1 Env Glycans."

Dr. Koni's project is one of 104 grants recently announced by the Gates Foundation for the first funding round of Grand Challenges Explorations, an initiative to help scientists around the world explore bold, new solutions for health challenges in developing countries. The grants were provided to all levels of scientists in 22 countries and five continents.

To receive funding, Dr. Koni showed in a two-page application how his idea falls outside current scientific paradigms and could lead to significant advances in global health if successful.

His goal is to develop a vaccine against HIV, a virus that is notoriously slippery, constantly mutating itself to avoid being targeted by the immune system. In fact, the dynamic of this virus is one reason vaccines to date have failed, Dr. Koni said. But he thinks there may be chinks in the armor. Like many cells in the body, HIV and HIV-infected cells are sugar-coated. In fact, one role of this complex carbohydrate shield is believed to be protecting HIV from attack. However there are some consistencies in the sugar coating which Dr. Koni believes are critical to the virus and may be good vaccine targets.

As a first step, the immunologist is working to develop antibodies to these segments of the sugar coating with the idea that they are sites of potential vulnerability for the durable virus. "My idea is that these areas are always conserved and are consistent for a reason," said Dr. Koni. While his goal is to develop a protective vaccine, Dr. Koni said if he's successful in his pursuit, the antibodies may provide new targeted treatment strategies as well.

"I congratulate each individual who took the initiative to share their idea with us to help fight the world's most serious diseases," said Dr. Tachi Yamada, president of the Gates Foundation's Global Health Program. "The number of creative approaches we received exceeded our highest aspirations. Projects from this initial pool of grants have the potential to transform health in developing countries, and I will be rooting for their success."

###

About Grand Challenges Explorations

Grand Challenges Explorations is a five-year $100 million initiative of the Gates Foundation to promote innovation in global health. The program uses an agile, streamlined grant process – applications are limited to two pages, and preliminary data are not required. Proposals are reviewed and selected by a committee of foundation staff and external experts, and grant decisions are made within approximately three months of the close of the funding round.

Applications for the second round of Grand Challenges Explorations are being accepted through November 2, 2008, and topics for the third round will be announced in early 2009. Grant application instructions, including the list of topic areas in which proposals are currently being accepted, are available at www.gcgh.org/explorations.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.